SlideShare a Scribd company logo
1 of 36
Download to read offline
Merck KGaA
Darmstadt, Germany
Jeffrey Barna, Habib Horry
A Cost Analysis and
Evaluation of Perfused
Seed Train Scenarios
Through Process Modeling
2
The life science business of
Merck KGaA, Darmstadt, Germany
operates as MilliporeSigma
in the U.S. and Canada.
Part II of the BioContinuum™ Seed Train Platform webinar series:
Novel Perfusion Filter and Controller for N-1 Application
 Considerations for a scalable cell retention device for perfusion applications
 Case study demonstrating capabilities of novel perfusion filter and controller for intensified upstream
processing
Previous Webinar
3
0
0
0Agenda
Introduction to Perfused Seed
Trains1
Model Assumptions and Plan2
Single Bioreactor Scenarios3
0 Multiple Bioreactor Scenarios4
0
0
0Agenda
Introduction to Perfused Seed
Trains1
Model Assumptions and Plan2
Single Bioreactor Scenarios3
0 Multiple Bioreactor Scenarios4
Speed
Reduce new facility build
times by 70%. Compress
production lead time by
80%.
Quality
10X robustness.
90% reduction in cost of
poor quality.
Flexibility
Reduce product change-over
time by 90%.
Cost
90% reduction in cost to
manufacture and CAPEX.
Business
Drivers
Market
Growth
Uncertainty
New Product
Classes
Cost
Pressure
Market
Trends
Market Trends, Business Drivers and Key Enablers to
Drive Next Generation BioProcessing:
Process
Intensification
Process
Analytics
Software &
Automation
Key
Enablers
Single Use
6
less
footprint
Less
capital
reduction in
construction time
reduction
OPEX
Reduction in
cost of quality
90%
90%
70%
60%
90%
Paradigm Shift:
The Facility of the Future will require a
transformation in how biologics are
developed and manufactured
Process
Format
Analytics
Digital Controlled
Inline
Single Use
Intensified
Integrated
Real Time
Closed
Connected
Autonomous
Predictive
Sterile
Continuous
7
Upstream Process Intensification for mAbs
A Multitude of Strategies all based on perfusion technology
Batch
x
1-2ml
each
10-30 x106 vc.ml-1
N-1
or
x
Batch
N
Fed Batch
MCB/MWCB INOCULATION TRAIN
SEED TRAIN
PRODUCTION
CRD
Perfusion
CRD
50-100 x106vc.ml-1
or or
4.5ml 50-500ml bagCRD
CRD
Perfusion
N
CRD
Continuous protein harvest
• Steady State Perfusion
• Dynamic Perfusion
Single protein harvest
• High Seed Fed batch
• Ultrahigh VCD Fed-Batch
• Concentrated Fed-Batch
Production
medium
Cryo Medium
Perfused Seed Train Processes
Can be utilized with any production method
Perfusion-based Production and Harvest processes
Continuous vs. single protein harvest, High cell densities, long durations
Expansion
medium
Cell Culture Media Formulations
Enabling intensified seed and production trains
High Qp
Low CSPR
Low OUR
High Shear resistance
Perfusion Optimized Cell Line
Maximizing protein yield and quality in perfusion operations
8
Definition
Perfused Seed Train
14 days
10 days
Conventional
Fed-Batch
(~ 0.2 E6 vc/mL)
High Seed
Fed-Batch
(~ 5 E6 vc/mL)
Conventional
(Batch N-1)
3 days3 days3 days3 days
or
5 days
Compressed
Seed Train
High Seed
(N-1 only)
High Seed
(N-1 & N-2)
Compressed Seed Train: facility utilization and reduced footprint
High-Seed: increased manufacturing capacity, facility utilization
8 days
or
3 days3 days3 days
10 days
or
3 days3 days3 days3 days
5 days8 days
or
3 days3 days3 days
9
0
0
0Agenda
Introduction to Perfused Seed
Trains1
Model Assumptions and Plan2
Single Bioreactor Scenarios3
0 Multiple Bioreactor Scenarios4
11
What is Biosolve®?
• Excel-based process model from BioPharm Services
• Calculates process economics
• Database of industry averages with the option for user-
specific information
Benefits of Process Modeling
• Focus on the “holistic process”
• Side-by-side evaluation of alternatives
• Can run “what if”, sensitivity analyses
• Clear communication of value
Unique Intensified Operation Modules of
Process Modeling
• Perfusion seed train and production options
• Continuous chromatography
• Flow through polishing
• Single-pass TFF
Biosolve®
The Benefits of Process Modeling (Value Modeling)
Perfused Seed Train
Model Assumptions
14 days
10 days
Conventional
Fed-Batch
(~ 0.2 E6 vc/mL)
High Seed
Fed-Batch
(~ 5 E6 vc/mL)
Conventional
(Batch N-1)
3 days3 days3 days3 days
or
5 days
Compressed
Seed Train
High Seed
(N-1 only)
High Seed
(N-1 & N-2)
8 days
or
3 days3 days3 days
10 days
or
3 days3 days3 days3 days
5 days8 days
or
3 days3 days3 days
12
Models to be
tested:
Perfused Seed Train
Model Assumptions
14 days
10 days
Conventional
Fed-Batch
(~ 0.2 E6 vc/mL)
High Seed
Fed-Batch
(~ 5 E6 vc/mL)
Conventional
(Batch N-1)
3 days
10L
3 days
100mL
3 days
30mL
5 days
60L,200L
Compressed
Seed Train
High Seed
(N-1 only)
High Seed
(N-1 & N-2)
13
Models to be
tested:
3 days
400mL
3 days
2L
125mL 500mL 2X500mL 2X3L 20L
200L
2000L
7 days
10L
20L
3 days
10L
20L
9 days
60L,200L
200L
7 days
10L
20L
4 days
200L
200L
Same as above
Same as above
Same as above
2000L
Each model contains a
traditional downstream!
Scope
14
• Constant production titer
• Constant production duration
• Constant production titer, 3:1 P/S
• Constant production titer, 2:1 P/S
• Constant production titer, 1:1 P/S
• Constant production duration, 3:1 P/S
• Constant production duration, 2:1 P/S
• Constant production duration, 1:1 P/S
Proposed Scenarios
Models: Conventional (Batch N-1), Compressed Seed Train, High Seed (pN-1), High Seed (pN-2/pN-1)
Goal Gain an understanding of the potential benefits of perfused seed trains through Biosolve®
Single Bioreactor Multiple Bioreactors (6)
14 days
4 g/L
vs. 10 days
4 g/L
Traditional High Seed
14 days
>4 g/L
Scope
15
• Constant production titer, 3:1 P/S
• Constant production titer, 2:1 P/S
• Constant production titer, 1:1 P/S
• Constant production duration, 3:1 P/S
• Constant production duration, 2:1 P/S
• Constant production duration, 1:1 P/S
Proposed Scenarios
Models: Conventional (Batch N-1), Compressed Seed Train, High Seed (pN-1), High Seed (pN-2/pN-1)
Goal Gain an understanding of the potential benefits of perfused seed trains through Biosolve®
Multiple Bioreactors (6)
6 Bioreactors2 Seed Trains
3:1 Ratio
Scope
16
• Constant production titer, 3:1 P/S
• Constant production titer, 2:1 P/S
• Constant production titer, 1:1 P/S
• Constant production duration, 3:1 P/S
• Constant production duration, 2:1 P/S
• Constant production duration, 1:1 P/S
Proposed Scenarios
Models: Conventional (Batch N-1), Compressed Seed Train, High Seed (pN-1), High Seed (pN-2/pN-1)
Goal Gain an understanding of the potential benefits of perfused seed trains through Biosolve®
Multiple Bioreactors (6)
6 Bioreactors3 Seed Trains
2:1 Ratio
Scope
17
• Constant production titer, 3:1 P/S
• Constant production titer, 2:1 P/S
• Constant production titer, 1:1 P/S
• Constant production duration, 3:1 P/S
• Constant production duration, 2:1 P/S
• Constant production duration, 1:1 P/S
Proposed Scenarios
Models: Conventional (Batch N-1), Compressed Seed Train, High Seed (pN-1), High Seed (pN-2/pN-1)
Goal Gain an understanding of the potential benefits of perfused seed trains through Biosolve®
Multiple Bioreactors (6)
6 Bioreactors6 Seed Trains
1:1 Ratio
0
0
0Agenda
Introduction to Perfused Seed
Trains1
Model Assumptions and Plan2
Single Bioreactor Scenarios3
0 Multiple Bioreactor Scenarios4
Single Bioreactor, Constant Production Titer
19
CoG’s ($/g) 116.39 116.80 101.17 101.64
Throughput
(kg/yr)
90.18 90.18 125.25 125.25
Batches/yr 18 18 25 25
Assumptions
• 1 X 2000L Bioreactor
• 1 X Seed train
• 4 g/L titer
• Traditional: 14 day production
• High Seed: 10 day production
• ~13.5% reduction in CoG’s by
switching to perfused seed train
• Increased throughput as well;
decreased production duration
increases batches/yr
• Cost reduction driven by higher
throughput; brings down capital
High Seed Fed Batch
Traditional Fed Batch
Single Bioreactor, Constant Production Duration
20
Assumptions
• 1 X 2000L Bioreactor
• 1 X Seed train
• Traditional: 14 day production
• High Seed: 14 day production
• Experimental data suggests titer can
increase 2-3X through high seeding
production
• Traditional seed train was compared
to perfused N-1 seed train with
varying production titers
• Higher throughput drives down all
costs; increased product mass per
batch
High Seed Fed Batch
CoG’s ($/g)
116.4 101.2 120.1 90.6 75.6 64.0 57.0
Throughput
(kg/yr)
90.18 125.25 90.18 135.27 180.36 225.45 270.54
Batches/yr
18 25 18 18 18 18 18
Single Bioreactor, Constant Production Duration
21
Assumptions
• 1 X 2000L Bioreactor
• 1 X Seed train
• Traditional: 14 day production
• High Seed: 14 day production
Seed Train Titer
Total
CoG’s
($/g)
%
Reduction
Traditional 4 g/L 116.39
pN-1 6 g/L 90.56 22%
pN-1 8 g/L 75.56 35%
pN-1 10 g/L 63.98 45%
pN-1 12 g/L 56.99 51%
High Seed Fed Batch
CoG’s ($/g)
116.4 101.2 120.1 90.6 75.6 64.0 57.0
Throughput
(kg/yr)
90.18 125.25 90.18 135.27 180.36 225.45 270.54
Batches/yr
18 25 18 18 18 18 18
Single Bioreactor Scenarios - Summary
22
Constant Production Titer
14 days
4 g/L
vs. 10 days
4 g/L
❖ High Seed options increase batch/yr
and throughput
18 –> 25 batch/yr
90 –> 125 kg/yr
❖ Drives capital CoG’s down, total CoG’s
down 13.5%
Constant Production Duration
Traditional High Seed
❖ Greater benefit observed through
keeping constant production duration
❖ Overall CoG’s reduced 22-51%
❖ Throughput increase 50-200%;
proportional to titer increase
❖ No change in batches/yr
Conventional
(Batch N-1)
Compressed
Seed Train
High Seed
(N-1 only)
High Seed
(N-1 & N-2)
14 days
4 g/L
vs. 14 days
>4 g/L
Traditional High Seed
Conventional
(Batch N-1)
Compressed
Seed Train
High Seed
(N-1 only)
High Seed
(N-1 & N-2)
0
0
0Agenda
Introduction to Perfused Seed
Trains1
Model Assumptions and Plan2
Single Bioreactor Scenarios3
0 Multiple Bioreactor Scenarios4
3:1 Production/Seed Train Ratio
24
Assumptions
• 6 X 2000L Bioreactor
• 2 X Seed train
• 4 g/L titer
• Traditional: 14 day production
• High Seed: 10 day production
CoG’s ($/g) 67.38 77.25 85.46 82.80
Throughput
(kg/yr) 495.99 315.63 275.55 315.63
Batches/yr 99 63 55 63
• No cost or throughput
benefit for 3:1
production/seed train ratio
• With 6 bioreactors,
production is no longer
bottleneck
3:1 Production/Seed Train Ratio
25
Assumptions
• 6 X 2000L Bioreactor
• 2 X Seed train
• 4 g/L titer
• Traditional: 14 day production
• High Seed: 10 day production
• No cost or throughput
benefit for 3:1
production/seed train ratio
• With 6 bioreactors,
production is no longer
bottleneck
Process
Bottleneck
Unit Op
Bottleneck
Time
(days/batch)
Batches/yr
Traditional N-1 2.64 99
Compressed Seed Fed
Batch
Perfused
Rocker
4.12 63
Perfused Seed (pN-1) N-1 4.76 55
Perfused Seed (pN-2/pN-1) N-2 Rocker 4.12 63
2:1 Production/Seed Train Ratio
26
Assumptions
• 6 X 2000L Bioreactor
• 3 X Seed train
• 4 g/L titer
• Traditional: 14 day production
• High Seed: 10 day production
CoG’s ($/g) 65.88 67.58 75.03 73.08
Throughput
(kg/yr) 551.11 475.95 410.82 475.95
Batches/yr 110 95 82 95
• Similarly to 3:1, no cost or
throughput benefit for 2:1
production/seed train ratio
• Bottlenecking effect is less
pronounced, due to extra
seed train
2:1 Production/Seed Train Ratio
27
Assumptions
• 6 X 2000L Bioreactor
• 3 X Seed train
• 4 g/L titer
• Traditional: 14 day production
• High Seed: 10 day production
Process
Bottleneck
Unit Op
Bottleneck
Time
(days/batch)
Batches/yr
Traditional Production 2.39 110
Compressed Seed Fed
Batch
Perfused
Rocker
2.74 95
Perfused Seed (pN-1) N-1 3.17 82
Perfused Seed (pN-2/pN-1) N-2 Rocker 2.74 95
• Similarly to 3:1, no cost or
throughput benefit for 2:1
production/seed train ratio
• Bottlenecking effect is less
pronounced, due to extra
seed train
1:1 Production/Seed Train Ratio
28
Assumptions
• 6 X 2000L Bioreactor
• 6 X Seed train
• 4 g/L titer
• Traditional: 14 day production
• High Seed: 10 day production
CoG’s ($/g)
66.88 65.35 65.06 66.52
Throughput
(kg/yr)
551.11 546.10 761.53 761.53
Batches/yr
110 109 152 152
• Negligible CoG’s differences,
though significant increase in
throughput for high seed fed
batch
• With 1:1 ratio, production
becomes bottleneck again;
decreased HiSeed production
duration increases throughput
1:1 Production/Seed Train Ratio
29
Assumptions
• 6 X 2000L Bioreactor
• 6 X Seed train
• 4 g/L titer
• Traditional: 14 day production
• High Seed: 10 day production
Process
Bottleneck
Unit Op
Bottleneck
Time
(days/batch)
Batches/yr
Traditional Production 2.39 110
Compressed Seed Fed
Batch
Production 2.40 109
Perfused Seed (pN-1) Production 1.73 152
Perfused Seed (pN-2/pN-1) Production 1.73 152
• Negligible CoG’s differences,
though significant increase in
throughput for high seed fed
batch
• With 1:1 ratio, production
becomes bottleneck again;
decreased HiSeed production
duration increases throughput
Increased Titer with High Seed Production – 3:1 P/S ratio
30
Assumptions
• 3:1 P/S ratio
• 6 X 2000L Bioreactor
• 2 X Seed train
• Traditional: 14 day production
• High Seed: 14 day production
CoG’s ($/g) 67.38 85.46 85.46 62.49 52.01 43.78 39.39
Throughput
(kg/yr) 495.99 275.55 275.55 413.33 551.11 688.88 826.66
Batches/yr 99 55 55 55 55 55 55
High Seed Fed Batch
• As seen earlier, process
bottlenecks reduce batches/yr
for perfused seed options at 3:1
P/S ratio
• Increased titer offsets that
reduction in most cases,
ultimately increasing throughput
• Higher throughput and product
per batch drives down CoG’s
Increased Titer with High Seed Production – 2:1 P/S Ratio
31
Assumptions
• 2:1 P/S ratio
• 6 X 2000L Bioreactor
• 3 X Seed train
• Traditional: 14 day production
• High Seed: 14 day production
CoG’s ($/g) 65.88 75.03 75.03 54.67 45.75 38.49 34.64
Throughput
(kg/yr) 551.11 410.82 410.82 616.24 821.65 1027.06 1232.57
Batches/yr 110 82 82 82 82 82 82
High Seed Fed Batch
• Similar trend observed
• With bottleneck effect
diminishing, throughput
increase is larger
Increased Titer with High Seed Production – 1:1 P/S Ratio
32
Assumptions
• 1:1 P/S ratio
• 6 X 2000L Bioreactor
• 6 X Seed train
• Traditional: 14 day production
• High Seed: 14 day production
CoG’s ($/g) 66.88 65.06 70.79 51.46 43.08 36.17 32.67
Throughput
(kg/yr) 551.11 761.53 546.10 819.14 1092.19 1365.24 1638.29
Batches/yr 110 152 109 109 109 109 109
High Seed Fed Batch
• Again, for 1:1 P/S ratio,
production becomes
bottleneck
• Batches/yr more or less
constant
• Most significant increase
in throughput
Increased Titer with High Seed – Summary (6 Bioreactors)
33
• When considering the potential for increased
titer through high seed fed batch, virtually all
scenarios offer benefits
• For both CoG’s and throughput, most benefit is found
at 1:1 production/seed train ratio
• Decrease CoG’s 23-51%
• Increase throughput 65-230%
% CoG’s Reduction and % Throughout Increase calculated by comparing to Traditional 4 g/L process
Multiple Bioreactor Scenarios - Summary
34
Constant Production Titer
14 days
4 g/L
vs. 10 days
4 g/L
❖ No benefit observed in 3:1 and 2:1
P/S scenarios; bottleneck issues
❖ At 1:1 P/S ratio, throughput increase
due to increase batches/yr
109->152 batches/yr
Constant Production Duration
Traditional High Seed
❖ Overall CoG’s decrease and
throughput increase at all P/S ratios
❖ For 3:1 and 2:1 P/S ratios, batches/yr
is reduced, even with CoG’s and
throughput benefits
Conventional
(Batch N-1)
Compressed
Seed Train
High Seed
(N-1 only)
High Seed
(N-1 & N-2)
14 days
4 g/L
vs. 14 days
>4 g/L
Traditional High Seed
Conventional
(Batch N-1)
Compressed
Seed Train
High Seed
(N-1 only)
High Seed
(N-1 & N-2)
35
Implementing perfused seed trains can
bring down cost of manufacturing and
increase product throughput, all while
keeping production bioreactor in fed
batch mode
Perfused seed trains allow for high
seeding of production bioreactor, which
has the potential for achieving higher
titers, especially when incorporating a
strong media platform
Summary
If higher titers observed:
• Adding additional seed trains and production bioreactors at
1:1 ratio brings the most benefit
• CoG’s reduced 24-52%, kg/yr increase 65-230%
• Benefits even at 3:1 and 2:1, with additional benefit of
needing less batches per year
• 3:1 – CoG’s reduced 7-42%, kg/yr increase 11-67%
• 2:1 - CoG’s reduced 19-49%, kg/yr increase 24-149%
If higher titers are not observed:
• Single bioreactor scenarios still see CoG’s reduced by 13.5%
and throughput increase of 39% at shorter high seed FB
duration
• Adding additional seed trains and production bioreactors at
1:1 ratio increases throughput
The vibrant M and BioContinuum are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their
respective owners. Detailed information on trademarks is available via publicly accessible resources.
© 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

More Related Content

What's hot

Process Intensification for future bioprocessing
Process Intensification for future bioprocessingProcess Intensification for future bioprocessing
Process Intensification for future bioprocessingMilliporeSigma
 
How to reach High Plasma Protein Concentration with Single-Pass TFF
How to reach High Plasma Protein Concentration with Single-Pass TFFHow to reach High Plasma Protein Concentration with Single-Pass TFF
How to reach High Plasma Protein Concentration with Single-Pass TFFMerck Life Sciences
 
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...Merck Life Sciences
 
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...Merck Life Sciences
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Merck Life Sciences
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up MilliporeSigma
 
Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Driving Value in the Evolution Toward Continuous Monoclonal Antibody ProcessingDriving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Driving Value in the Evolution Toward Continuous Monoclonal Antibody ProcessingMilliporeSigma
 
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
Membrane Chromatography Solutions for Single-Use, Intensified mAb PurificationMembrane Chromatography Solutions for Single-Use, Intensified mAb Purification
Membrane Chromatography Solutions for Single-Use, Intensified mAb PurificationMilliporeSigma
 
Webinar: How to Develop a Regulatory-compliant Continued Process Verificatio...
Webinar: 	How to Develop a Regulatory-compliant Continued Process Verificatio...Webinar: 	How to Develop a Regulatory-compliant Continued Process Verificatio...
Webinar: How to Develop a Regulatory-compliant Continued Process Verificatio...MilliporeSigma
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...MilliporeSigma
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationMilliporeSigma
 
Custom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Custom Affinity Chromatography for Vaccine Purification: A New PD ParadigmCustom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Custom Affinity Chromatography for Vaccine Purification: A New PD ParadigmMilliporeSigma
 
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformMerck Life Sciences
 

What's hot (14)

Process Intensification for future bioprocessing
Process Intensification for future bioprocessingProcess Intensification for future bioprocessing
Process Intensification for future bioprocessing
 
How to reach High Plasma Protein Concentration with Single-Pass TFF
How to reach High Plasma Protein Concentration with Single-Pass TFFHow to reach High Plasma Protein Concentration with Single-Pass TFF
How to reach High Plasma Protein Concentration with Single-Pass TFF
 
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
 
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 
Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Driving Value in the Evolution Toward Continuous Monoclonal Antibody ProcessingDriving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
 
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
Membrane Chromatography Solutions for Single-Use, Intensified mAb PurificationMembrane Chromatography Solutions for Single-Use, Intensified mAb Purification
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
 
Webinar: How to Develop a Regulatory-compliant Continued Process Verificatio...
Webinar: 	How to Develop a Regulatory-compliant Continued Process Verificatio...Webinar: 	How to Develop a Regulatory-compliant Continued Process Verificatio...
Webinar: How to Develop a Regulatory-compliant Continued Process Verificatio...
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
Custom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Custom Affinity Chromatography for Vaccine Purification: A New PD ParadigmCustom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Custom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
 
Process Scale Chromatography
Process Scale ChromatographyProcess Scale Chromatography
Process Scale Chromatography
 
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train Platform
 

Similar to A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Process Modeling

The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformMilliporeSigma
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationMerck Life Sciences
 
Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Driving Value in the Evolution Toward Continuous Monoclonal Antibody ProcessingDriving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Driving Value in the Evolution Toward Continuous Monoclonal Antibody ProcessingMerck Life Sciences
 
SMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.pptSMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.ppthirbogeremew2
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Merck Life Sciences
 
Cell Line Development: Reducing timelines and increasing titres
Cell Line Development: Reducing timelines and increasing titres Cell Line Development: Reducing timelines and increasing titres
Cell Line Development: Reducing timelines and increasing titres fujifilmdiosynth
 
Exploring Intensified Seed Train Through Advancements in Perfusion Processing...
Exploring Intensified Seed Train Through Advancements in Perfusion Processing...Exploring Intensified Seed Train Through Advancements in Perfusion Processing...
Exploring Intensified Seed Train Through Advancements in Perfusion Processing...Merck Life Sciences
 
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...fujifilmdiosynth
 
Estell
EstellEstell
EstellNashLS
 
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...KBI Biopharma
 
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...KBI Biopharma
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesMilliporeSigma
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesMerck Life Sciences
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...MilliporeSigma
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Merck Life Sciences
 
Media and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMedia and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMerck Life Sciences
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsMerck Life Sciences
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsMilliporeSigma
 
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...KBI Biopharma
 
Sartorius Cell Line Development
Sartorius Cell Line Development Sartorius Cell Line Development
Sartorius Cell Line Development Raymond Goyco, III
 

Similar to A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Process Modeling (20)

The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train Platform
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Driving Value in the Evolution Toward Continuous Monoclonal Antibody ProcessingDriving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
 
SMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.pptSMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.ppt
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
 
Cell Line Development: Reducing timelines and increasing titres
Cell Line Development: Reducing timelines and increasing titres Cell Line Development: Reducing timelines and increasing titres
Cell Line Development: Reducing timelines and increasing titres
 
Exploring Intensified Seed Train Through Advancements in Perfusion Processing...
Exploring Intensified Seed Train Through Advancements in Perfusion Processing...Exploring Intensified Seed Train Through Advancements in Perfusion Processing...
Exploring Intensified Seed Train Through Advancements in Perfusion Processing...
 
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
 
Estell
EstellEstell
Estell
 
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
 
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell Lines
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell Lines
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...
 
Media and Process Development for Seed Train Intensification
Media and Process Development for Seed Train IntensificationMedia and Process Development for Seed Train Intensification
Media and Process Development for Seed Train Intensification
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey Platforms
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey Platforms
 
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
 
Sartorius Cell Line Development
Sartorius Cell Line Development Sartorius Cell Line Development
Sartorius Cell Line Development
 

More from Merck Life Sciences

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeMerck Life Sciences
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...Merck Life Sciences
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationMerck Life Sciences
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Merck Life Sciences
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...Merck Life Sciences
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Merck Life Sciences
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...Merck Life Sciences
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsMerck Life Sciences
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Merck Life Sciences
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesMerck Life Sciences
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Merck Life Sciences
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...Merck Life Sciences
 
Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Merck Life Sciences
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Merck Life Sciences
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsMerck Life Sciences
 
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Merck Life Sciences
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...Merck Life Sciences
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...Merck Life Sciences
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesMerck Life Sciences
 

More from Merck Life Sciences (20)

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide Alternative
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein Purification
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical Audits
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
 
Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
 
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
 

Recently uploaded

Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service DehradunDehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service DehradunNiamh verma
 
Hot Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
Hot  Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In LudhianaHot  Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
Hot Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In LudhianaRussian Call Girls in Ludhiana
 
Call Girls Service Chandigarh Grishma ❤️🍑 9907093804 👄🫦 Independent Escort Se...
Call Girls Service Chandigarh Grishma ❤️🍑 9907093804 👄🫦 Independent Escort Se...Call Girls Service Chandigarh Grishma ❤️🍑 9907093804 👄🫦 Independent Escort Se...
Call Girls Service Chandigarh Grishma ❤️🍑 9907093804 👄🫦 Independent Escort Se...High Profile Call Girls Chandigarh Aarushi
 
VIP Call Girl Sector 88 Gurgaon Delhi Just Call Me 9899900591
VIP Call Girl Sector 88 Gurgaon Delhi Just Call Me 9899900591VIP Call Girl Sector 88 Gurgaon Delhi Just Call Me 9899900591
VIP Call Girl Sector 88 Gurgaon Delhi Just Call Me 9899900591adityaroy0215
 
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in LucknowRussian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknowgragteena
 
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Sheetaleventcompany
 
Hot Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
Hot  Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In ChandigarhHot  Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
Hot Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In ChandigarhVip call girls In Chandigarh
 
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...High Profile Call Girls Chandigarh Aarushi
 
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar SumanCall Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar SumanCall Girls Service Chandigarh Ayushi
 
No Advance 9053900678 Chandigarh Call Girls , Indian Call Girls For Full Ni...
No Advance 9053900678 Chandigarh  Call Girls , Indian Call Girls  For Full Ni...No Advance 9053900678 Chandigarh  Call Girls , Indian Call Girls  For Full Ni...
No Advance 9053900678 Chandigarh Call Girls , Indian Call Girls For Full Ni...Vip call girls In Chandigarh
 
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.ktanvi103
 
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...indiancallgirl4rent
 
Vip sexy Call Girls Service In Sector 137,9999965857 Young Female Escorts Ser...
Vip sexy Call Girls Service In Sector 137,9999965857 Young Female Escorts Ser...Vip sexy Call Girls Service In Sector 137,9999965857 Young Female Escorts Ser...
Vip sexy Call Girls Service In Sector 137,9999965857 Young Female Escorts Ser...Call Girls Noida
 
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Dehradun Call Girls Service 7017441440 Real Russian Girls Looking Models
Dehradun Call Girls Service 7017441440 Real Russian Girls Looking ModelsDehradun Call Girls Service 7017441440 Real Russian Girls Looking Models
Dehradun Call Girls Service 7017441440 Real Russian Girls Looking Modelsindiancallgirl4rent
 
Call Girl Gurgaon Saloni 9711199012 Independent Escort Service Gurgaon
Call Girl Gurgaon Saloni 9711199012 Independent Escort Service GurgaonCall Girl Gurgaon Saloni 9711199012 Independent Escort Service Gurgaon
Call Girl Gurgaon Saloni 9711199012 Independent Escort Service GurgaonCall Girls Service Gurgaon
 

Recently uploaded (20)

Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service DehradunDehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
Dehradun Call Girls Service ❤️🍑 9675010100 👄🫦Independent Escort Service Dehradun
 
Hot Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
Hot  Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In LudhianaHot  Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
Hot Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
 
Call Girls Service Chandigarh Grishma ❤️🍑 9907093804 👄🫦 Independent Escort Se...
Call Girls Service Chandigarh Grishma ❤️🍑 9907093804 👄🫦 Independent Escort Se...Call Girls Service Chandigarh Grishma ❤️🍑 9907093804 👄🫦 Independent Escort Se...
Call Girls Service Chandigarh Grishma ❤️🍑 9907093804 👄🫦 Independent Escort Se...
 
VIP Call Girl Sector 88 Gurgaon Delhi Just Call Me 9899900591
VIP Call Girl Sector 88 Gurgaon Delhi Just Call Me 9899900591VIP Call Girl Sector 88 Gurgaon Delhi Just Call Me 9899900591
VIP Call Girl Sector 88 Gurgaon Delhi Just Call Me 9899900591
 
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in LucknowRussian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
Russian Escorts Aishbagh Road * 9548273370 Naughty Call Girls Service in Lucknow
 
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
 
Hot Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
Hot  Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In ChandigarhHot  Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
Hot Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
 
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
Russian Call Girls in Chandigarh Ojaswi ❤️🍑 9907093804 👄🫦 Independent Escort ...
 
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar SumanCall Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
 
No Advance 9053900678 Chandigarh Call Girls , Indian Call Girls For Full Ni...
No Advance 9053900678 Chandigarh  Call Girls , Indian Call Girls  For Full Ni...No Advance 9053900678 Chandigarh  Call Girls , Indian Call Girls  For Full Ni...
No Advance 9053900678 Chandigarh Call Girls , Indian Call Girls For Full Ni...
 
VIP Call Girls Lucknow Isha 🔝 9719455033 🔝 🎶 Independent Escort Service Lucknow
VIP Call Girls Lucknow Isha 🔝 9719455033 🔝 🎶 Independent Escort Service LucknowVIP Call Girls Lucknow Isha 🔝 9719455033 🔝 🎶 Independent Escort Service Lucknow
VIP Call Girls Lucknow Isha 🔝 9719455033 🔝 🎶 Independent Escort Service Lucknow
 
Russian Call Girls in Dehradun Komal 🔝 7001305949 🔝 📍 Independent Escort Serv...
Russian Call Girls in Dehradun Komal 🔝 7001305949 🔝 📍 Independent Escort Serv...Russian Call Girls in Dehradun Komal 🔝 7001305949 🔝 📍 Independent Escort Serv...
Russian Call Girls in Dehradun Komal 🔝 7001305949 🔝 📍 Independent Escort Serv...
 
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
Call Now ☎ 9999965857 !! Call Girls in Hauz Khas Escort Service Delhi N.C.R.
 
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
 
Call Girls in Lucknow Esha 🔝 8923113531 🔝 🎶 Independent Escort Service Lucknow
Call Girls in Lucknow Esha 🔝 8923113531  🔝 🎶 Independent Escort Service LucknowCall Girls in Lucknow Esha 🔝 8923113531  🔝 🎶 Independent Escort Service Lucknow
Call Girls in Lucknow Esha 🔝 8923113531 🔝 🎶 Independent Escort Service Lucknow
 
Vip sexy Call Girls Service In Sector 137,9999965857 Young Female Escorts Ser...
Vip sexy Call Girls Service In Sector 137,9999965857 Young Female Escorts Ser...Vip sexy Call Girls Service In Sector 137,9999965857 Young Female Escorts Ser...
Vip sexy Call Girls Service In Sector 137,9999965857 Young Female Escorts Ser...
 
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
 
Model Call Girl in Subhash Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Subhash Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Subhash Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Subhash Nagar Delhi reach out to us at 🔝9953056974🔝
 
Dehradun Call Girls Service 7017441440 Real Russian Girls Looking Models
Dehradun Call Girls Service 7017441440 Real Russian Girls Looking ModelsDehradun Call Girls Service 7017441440 Real Russian Girls Looking Models
Dehradun Call Girls Service 7017441440 Real Russian Girls Looking Models
 
Call Girl Gurgaon Saloni 9711199012 Independent Escort Service Gurgaon
Call Girl Gurgaon Saloni 9711199012 Independent Escort Service GurgaonCall Girl Gurgaon Saloni 9711199012 Independent Escort Service Gurgaon
Call Girl Gurgaon Saloni 9711199012 Independent Escort Service Gurgaon
 

A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Process Modeling

  • 1. Merck KGaA Darmstadt, Germany Jeffrey Barna, Habib Horry A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Process Modeling
  • 2. 2 The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
  • 3. Part II of the BioContinuum™ Seed Train Platform webinar series: Novel Perfusion Filter and Controller for N-1 Application  Considerations for a scalable cell retention device for perfusion applications  Case study demonstrating capabilities of novel perfusion filter and controller for intensified upstream processing Previous Webinar 3
  • 4. 0 0 0Agenda Introduction to Perfused Seed Trains1 Model Assumptions and Plan2 Single Bioreactor Scenarios3 0 Multiple Bioreactor Scenarios4
  • 5. 0 0 0Agenda Introduction to Perfused Seed Trains1 Model Assumptions and Plan2 Single Bioreactor Scenarios3 0 Multiple Bioreactor Scenarios4
  • 6. Speed Reduce new facility build times by 70%. Compress production lead time by 80%. Quality 10X robustness. 90% reduction in cost of poor quality. Flexibility Reduce product change-over time by 90%. Cost 90% reduction in cost to manufacture and CAPEX. Business Drivers Market Growth Uncertainty New Product Classes Cost Pressure Market Trends Market Trends, Business Drivers and Key Enablers to Drive Next Generation BioProcessing: Process Intensification Process Analytics Software & Automation Key Enablers Single Use 6
  • 7. less footprint Less capital reduction in construction time reduction OPEX Reduction in cost of quality 90% 90% 70% 60% 90% Paradigm Shift: The Facility of the Future will require a transformation in how biologics are developed and manufactured Process Format Analytics Digital Controlled Inline Single Use Intensified Integrated Real Time Closed Connected Autonomous Predictive Sterile Continuous 7
  • 8. Upstream Process Intensification for mAbs A Multitude of Strategies all based on perfusion technology Batch x 1-2ml each 10-30 x106 vc.ml-1 N-1 or x Batch N Fed Batch MCB/MWCB INOCULATION TRAIN SEED TRAIN PRODUCTION CRD Perfusion CRD 50-100 x106vc.ml-1 or or 4.5ml 50-500ml bagCRD CRD Perfusion N CRD Continuous protein harvest • Steady State Perfusion • Dynamic Perfusion Single protein harvest • High Seed Fed batch • Ultrahigh VCD Fed-Batch • Concentrated Fed-Batch Production medium Cryo Medium Perfused Seed Train Processes Can be utilized with any production method Perfusion-based Production and Harvest processes Continuous vs. single protein harvest, High cell densities, long durations Expansion medium Cell Culture Media Formulations Enabling intensified seed and production trains High Qp Low CSPR Low OUR High Shear resistance Perfusion Optimized Cell Line Maximizing protein yield and quality in perfusion operations 8
  • 9. Definition Perfused Seed Train 14 days 10 days Conventional Fed-Batch (~ 0.2 E6 vc/mL) High Seed Fed-Batch (~ 5 E6 vc/mL) Conventional (Batch N-1) 3 days3 days3 days3 days or 5 days Compressed Seed Train High Seed (N-1 only) High Seed (N-1 & N-2) Compressed Seed Train: facility utilization and reduced footprint High-Seed: increased manufacturing capacity, facility utilization 8 days or 3 days3 days3 days 10 days or 3 days3 days3 days3 days 5 days8 days or 3 days3 days3 days 9
  • 10. 0 0 0Agenda Introduction to Perfused Seed Trains1 Model Assumptions and Plan2 Single Bioreactor Scenarios3 0 Multiple Bioreactor Scenarios4
  • 11. 11 What is Biosolve®? • Excel-based process model from BioPharm Services • Calculates process economics • Database of industry averages with the option for user- specific information Benefits of Process Modeling • Focus on the “holistic process” • Side-by-side evaluation of alternatives • Can run “what if”, sensitivity analyses • Clear communication of value Unique Intensified Operation Modules of Process Modeling • Perfusion seed train and production options • Continuous chromatography • Flow through polishing • Single-pass TFF Biosolve® The Benefits of Process Modeling (Value Modeling)
  • 12. Perfused Seed Train Model Assumptions 14 days 10 days Conventional Fed-Batch (~ 0.2 E6 vc/mL) High Seed Fed-Batch (~ 5 E6 vc/mL) Conventional (Batch N-1) 3 days3 days3 days3 days or 5 days Compressed Seed Train High Seed (N-1 only) High Seed (N-1 & N-2) 8 days or 3 days3 days3 days 10 days or 3 days3 days3 days3 days 5 days8 days or 3 days3 days3 days 12 Models to be tested:
  • 13. Perfused Seed Train Model Assumptions 14 days 10 days Conventional Fed-Batch (~ 0.2 E6 vc/mL) High Seed Fed-Batch (~ 5 E6 vc/mL) Conventional (Batch N-1) 3 days 10L 3 days 100mL 3 days 30mL 5 days 60L,200L Compressed Seed Train High Seed (N-1 only) High Seed (N-1 & N-2) 13 Models to be tested: 3 days 400mL 3 days 2L 125mL 500mL 2X500mL 2X3L 20L 200L 2000L 7 days 10L 20L 3 days 10L 20L 9 days 60L,200L 200L 7 days 10L 20L 4 days 200L 200L Same as above Same as above Same as above 2000L Each model contains a traditional downstream!
  • 14. Scope 14 • Constant production titer • Constant production duration • Constant production titer, 3:1 P/S • Constant production titer, 2:1 P/S • Constant production titer, 1:1 P/S • Constant production duration, 3:1 P/S • Constant production duration, 2:1 P/S • Constant production duration, 1:1 P/S Proposed Scenarios Models: Conventional (Batch N-1), Compressed Seed Train, High Seed (pN-1), High Seed (pN-2/pN-1) Goal Gain an understanding of the potential benefits of perfused seed trains through Biosolve® Single Bioreactor Multiple Bioreactors (6) 14 days 4 g/L vs. 10 days 4 g/L Traditional High Seed 14 days >4 g/L
  • 15. Scope 15 • Constant production titer, 3:1 P/S • Constant production titer, 2:1 P/S • Constant production titer, 1:1 P/S • Constant production duration, 3:1 P/S • Constant production duration, 2:1 P/S • Constant production duration, 1:1 P/S Proposed Scenarios Models: Conventional (Batch N-1), Compressed Seed Train, High Seed (pN-1), High Seed (pN-2/pN-1) Goal Gain an understanding of the potential benefits of perfused seed trains through Biosolve® Multiple Bioreactors (6) 6 Bioreactors2 Seed Trains 3:1 Ratio
  • 16. Scope 16 • Constant production titer, 3:1 P/S • Constant production titer, 2:1 P/S • Constant production titer, 1:1 P/S • Constant production duration, 3:1 P/S • Constant production duration, 2:1 P/S • Constant production duration, 1:1 P/S Proposed Scenarios Models: Conventional (Batch N-1), Compressed Seed Train, High Seed (pN-1), High Seed (pN-2/pN-1) Goal Gain an understanding of the potential benefits of perfused seed trains through Biosolve® Multiple Bioreactors (6) 6 Bioreactors3 Seed Trains 2:1 Ratio
  • 17. Scope 17 • Constant production titer, 3:1 P/S • Constant production titer, 2:1 P/S • Constant production titer, 1:1 P/S • Constant production duration, 3:1 P/S • Constant production duration, 2:1 P/S • Constant production duration, 1:1 P/S Proposed Scenarios Models: Conventional (Batch N-1), Compressed Seed Train, High Seed (pN-1), High Seed (pN-2/pN-1) Goal Gain an understanding of the potential benefits of perfused seed trains through Biosolve® Multiple Bioreactors (6) 6 Bioreactors6 Seed Trains 1:1 Ratio
  • 18. 0 0 0Agenda Introduction to Perfused Seed Trains1 Model Assumptions and Plan2 Single Bioreactor Scenarios3 0 Multiple Bioreactor Scenarios4
  • 19. Single Bioreactor, Constant Production Titer 19 CoG’s ($/g) 116.39 116.80 101.17 101.64 Throughput (kg/yr) 90.18 90.18 125.25 125.25 Batches/yr 18 18 25 25 Assumptions • 1 X 2000L Bioreactor • 1 X Seed train • 4 g/L titer • Traditional: 14 day production • High Seed: 10 day production • ~13.5% reduction in CoG’s by switching to perfused seed train • Increased throughput as well; decreased production duration increases batches/yr • Cost reduction driven by higher throughput; brings down capital High Seed Fed Batch Traditional Fed Batch
  • 20. Single Bioreactor, Constant Production Duration 20 Assumptions • 1 X 2000L Bioreactor • 1 X Seed train • Traditional: 14 day production • High Seed: 14 day production • Experimental data suggests titer can increase 2-3X through high seeding production • Traditional seed train was compared to perfused N-1 seed train with varying production titers • Higher throughput drives down all costs; increased product mass per batch High Seed Fed Batch CoG’s ($/g) 116.4 101.2 120.1 90.6 75.6 64.0 57.0 Throughput (kg/yr) 90.18 125.25 90.18 135.27 180.36 225.45 270.54 Batches/yr 18 25 18 18 18 18 18
  • 21. Single Bioreactor, Constant Production Duration 21 Assumptions • 1 X 2000L Bioreactor • 1 X Seed train • Traditional: 14 day production • High Seed: 14 day production Seed Train Titer Total CoG’s ($/g) % Reduction Traditional 4 g/L 116.39 pN-1 6 g/L 90.56 22% pN-1 8 g/L 75.56 35% pN-1 10 g/L 63.98 45% pN-1 12 g/L 56.99 51% High Seed Fed Batch CoG’s ($/g) 116.4 101.2 120.1 90.6 75.6 64.0 57.0 Throughput (kg/yr) 90.18 125.25 90.18 135.27 180.36 225.45 270.54 Batches/yr 18 25 18 18 18 18 18
  • 22. Single Bioreactor Scenarios - Summary 22 Constant Production Titer 14 days 4 g/L vs. 10 days 4 g/L ❖ High Seed options increase batch/yr and throughput 18 –> 25 batch/yr 90 –> 125 kg/yr ❖ Drives capital CoG’s down, total CoG’s down 13.5% Constant Production Duration Traditional High Seed ❖ Greater benefit observed through keeping constant production duration ❖ Overall CoG’s reduced 22-51% ❖ Throughput increase 50-200%; proportional to titer increase ❖ No change in batches/yr Conventional (Batch N-1) Compressed Seed Train High Seed (N-1 only) High Seed (N-1 & N-2) 14 days 4 g/L vs. 14 days >4 g/L Traditional High Seed Conventional (Batch N-1) Compressed Seed Train High Seed (N-1 only) High Seed (N-1 & N-2)
  • 23. 0 0 0Agenda Introduction to Perfused Seed Trains1 Model Assumptions and Plan2 Single Bioreactor Scenarios3 0 Multiple Bioreactor Scenarios4
  • 24. 3:1 Production/Seed Train Ratio 24 Assumptions • 6 X 2000L Bioreactor • 2 X Seed train • 4 g/L titer • Traditional: 14 day production • High Seed: 10 day production CoG’s ($/g) 67.38 77.25 85.46 82.80 Throughput (kg/yr) 495.99 315.63 275.55 315.63 Batches/yr 99 63 55 63 • No cost or throughput benefit for 3:1 production/seed train ratio • With 6 bioreactors, production is no longer bottleneck
  • 25. 3:1 Production/Seed Train Ratio 25 Assumptions • 6 X 2000L Bioreactor • 2 X Seed train • 4 g/L titer • Traditional: 14 day production • High Seed: 10 day production • No cost or throughput benefit for 3:1 production/seed train ratio • With 6 bioreactors, production is no longer bottleneck Process Bottleneck Unit Op Bottleneck Time (days/batch) Batches/yr Traditional N-1 2.64 99 Compressed Seed Fed Batch Perfused Rocker 4.12 63 Perfused Seed (pN-1) N-1 4.76 55 Perfused Seed (pN-2/pN-1) N-2 Rocker 4.12 63
  • 26. 2:1 Production/Seed Train Ratio 26 Assumptions • 6 X 2000L Bioreactor • 3 X Seed train • 4 g/L titer • Traditional: 14 day production • High Seed: 10 day production CoG’s ($/g) 65.88 67.58 75.03 73.08 Throughput (kg/yr) 551.11 475.95 410.82 475.95 Batches/yr 110 95 82 95 • Similarly to 3:1, no cost or throughput benefit for 2:1 production/seed train ratio • Bottlenecking effect is less pronounced, due to extra seed train
  • 27. 2:1 Production/Seed Train Ratio 27 Assumptions • 6 X 2000L Bioreactor • 3 X Seed train • 4 g/L titer • Traditional: 14 day production • High Seed: 10 day production Process Bottleneck Unit Op Bottleneck Time (days/batch) Batches/yr Traditional Production 2.39 110 Compressed Seed Fed Batch Perfused Rocker 2.74 95 Perfused Seed (pN-1) N-1 3.17 82 Perfused Seed (pN-2/pN-1) N-2 Rocker 2.74 95 • Similarly to 3:1, no cost or throughput benefit for 2:1 production/seed train ratio • Bottlenecking effect is less pronounced, due to extra seed train
  • 28. 1:1 Production/Seed Train Ratio 28 Assumptions • 6 X 2000L Bioreactor • 6 X Seed train • 4 g/L titer • Traditional: 14 day production • High Seed: 10 day production CoG’s ($/g) 66.88 65.35 65.06 66.52 Throughput (kg/yr) 551.11 546.10 761.53 761.53 Batches/yr 110 109 152 152 • Negligible CoG’s differences, though significant increase in throughput for high seed fed batch • With 1:1 ratio, production becomes bottleneck again; decreased HiSeed production duration increases throughput
  • 29. 1:1 Production/Seed Train Ratio 29 Assumptions • 6 X 2000L Bioreactor • 6 X Seed train • 4 g/L titer • Traditional: 14 day production • High Seed: 10 day production Process Bottleneck Unit Op Bottleneck Time (days/batch) Batches/yr Traditional Production 2.39 110 Compressed Seed Fed Batch Production 2.40 109 Perfused Seed (pN-1) Production 1.73 152 Perfused Seed (pN-2/pN-1) Production 1.73 152 • Negligible CoG’s differences, though significant increase in throughput for high seed fed batch • With 1:1 ratio, production becomes bottleneck again; decreased HiSeed production duration increases throughput
  • 30. Increased Titer with High Seed Production – 3:1 P/S ratio 30 Assumptions • 3:1 P/S ratio • 6 X 2000L Bioreactor • 2 X Seed train • Traditional: 14 day production • High Seed: 14 day production CoG’s ($/g) 67.38 85.46 85.46 62.49 52.01 43.78 39.39 Throughput (kg/yr) 495.99 275.55 275.55 413.33 551.11 688.88 826.66 Batches/yr 99 55 55 55 55 55 55 High Seed Fed Batch • As seen earlier, process bottlenecks reduce batches/yr for perfused seed options at 3:1 P/S ratio • Increased titer offsets that reduction in most cases, ultimately increasing throughput • Higher throughput and product per batch drives down CoG’s
  • 31. Increased Titer with High Seed Production – 2:1 P/S Ratio 31 Assumptions • 2:1 P/S ratio • 6 X 2000L Bioreactor • 3 X Seed train • Traditional: 14 day production • High Seed: 14 day production CoG’s ($/g) 65.88 75.03 75.03 54.67 45.75 38.49 34.64 Throughput (kg/yr) 551.11 410.82 410.82 616.24 821.65 1027.06 1232.57 Batches/yr 110 82 82 82 82 82 82 High Seed Fed Batch • Similar trend observed • With bottleneck effect diminishing, throughput increase is larger
  • 32. Increased Titer with High Seed Production – 1:1 P/S Ratio 32 Assumptions • 1:1 P/S ratio • 6 X 2000L Bioreactor • 6 X Seed train • Traditional: 14 day production • High Seed: 14 day production CoG’s ($/g) 66.88 65.06 70.79 51.46 43.08 36.17 32.67 Throughput (kg/yr) 551.11 761.53 546.10 819.14 1092.19 1365.24 1638.29 Batches/yr 110 152 109 109 109 109 109 High Seed Fed Batch • Again, for 1:1 P/S ratio, production becomes bottleneck • Batches/yr more or less constant • Most significant increase in throughput
  • 33. Increased Titer with High Seed – Summary (6 Bioreactors) 33 • When considering the potential for increased titer through high seed fed batch, virtually all scenarios offer benefits • For both CoG’s and throughput, most benefit is found at 1:1 production/seed train ratio • Decrease CoG’s 23-51% • Increase throughput 65-230% % CoG’s Reduction and % Throughout Increase calculated by comparing to Traditional 4 g/L process
  • 34. Multiple Bioreactor Scenarios - Summary 34 Constant Production Titer 14 days 4 g/L vs. 10 days 4 g/L ❖ No benefit observed in 3:1 and 2:1 P/S scenarios; bottleneck issues ❖ At 1:1 P/S ratio, throughput increase due to increase batches/yr 109->152 batches/yr Constant Production Duration Traditional High Seed ❖ Overall CoG’s decrease and throughput increase at all P/S ratios ❖ For 3:1 and 2:1 P/S ratios, batches/yr is reduced, even with CoG’s and throughput benefits Conventional (Batch N-1) Compressed Seed Train High Seed (N-1 only) High Seed (N-1 & N-2) 14 days 4 g/L vs. 14 days >4 g/L Traditional High Seed Conventional (Batch N-1) Compressed Seed Train High Seed (N-1 only) High Seed (N-1 & N-2)
  • 35. 35 Implementing perfused seed trains can bring down cost of manufacturing and increase product throughput, all while keeping production bioreactor in fed batch mode Perfused seed trains allow for high seeding of production bioreactor, which has the potential for achieving higher titers, especially when incorporating a strong media platform Summary If higher titers observed: • Adding additional seed trains and production bioreactors at 1:1 ratio brings the most benefit • CoG’s reduced 24-52%, kg/yr increase 65-230% • Benefits even at 3:1 and 2:1, with additional benefit of needing less batches per year • 3:1 – CoG’s reduced 7-42%, kg/yr increase 11-67% • 2:1 - CoG’s reduced 19-49%, kg/yr increase 24-149% If higher titers are not observed: • Single bioreactor scenarios still see CoG’s reduced by 13.5% and throughput increase of 39% at shorter high seed FB duration • Adding additional seed trains and production bioreactors at 1:1 ratio increases throughput
  • 36. The vibrant M and BioContinuum are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.